These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 66687)

  • 21. Hormonal predictors of prostate cancer.
    Sofikerim M; Eskicorapci S; Oruç O; Ozen H
    Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The hormonal profile in the polycystic ovary syndrome].
    Donát J; Kohoutek M; Donátová N; Lacinová V
    Cesk Gynekol; 1989 Nov; 54(9):684-8. PubMed ID: 2516481
    [No Abstract]   [Full Text] [Related]  

  • 23. Hormonal and testicular volume studies in cryptorchidism.
    Roselló PJ; Novoa R; Milazzo C
    Bol Asoc Med P R; 1982 Mar; 74(3):66-9. PubMed ID: 6127088
    [No Abstract]   [Full Text] [Related]  

  • 24. [Serum levels of luteinizing hormone, follicle-stimulating hormone, cortisol, testosterone and estradiol in viral hepatitis].
    Meller H; Halawa B
    Pol Tyg Lek; 1979 Sep; 34(37):1449-51. PubMed ID: 503947
    [No Abstract]   [Full Text] [Related]  

  • 25. Luteinizing hormone, adrenal androgenesis, and polycystic ovarian disease.
    Polansky S
    Obstet Gynecol; 1975 Apr; 45(4):451-4. PubMed ID: 1121374
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early and late long-term effects of vasectomy on serum testosterone, dihydrotestosterone, luteinizing hormone and follicle-stimulating hormone levels.
    Mo ZN; Huang X; Zhang SC; Yang JR
    J Urol; 1995 Dec; 154(6):2065-9. PubMed ID: 7500459
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Plasma testosterone: a sound criterion of the effectiveness of hormonal treatment of prostatic carcinoma].
    Maleeva A; Tsvetkov M; Kekhaĭova M
    Vutr Boles; 1980; 19(3):42-6. PubMed ID: 6771918
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of antiestrogen, antiandrogen, and the prolactin inhibitor 2 bromo-alpha-ergocriptine on the stromal tissue of human benign prostatic hyperplasia. Correlation of stereological data and plasma hormones.
    Bartsch G; Oberholzer M; Rohr HP
    Invest Urol; 1981 Jan; 18(4):308-12. PubMed ID: 6161105
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hormonal correlations in the polycystic ovary syndrome.
    Messina M; Milani P; Gentile L
    Boll Soc Ital Biol Sper; 1986 Jan; 62(1):31-5. PubMed ID: 3087390
    [No Abstract]   [Full Text] [Related]  

  • 30. [Correlation between gonadotropin regulation and Leydig cell function in male hypogonadism].
    Demisch K; Neubauer M; Schöffling K
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():1334-7. PubMed ID: 347776
    [No Abstract]   [Full Text] [Related]  

  • 31. Estrogen induction of luteinizing hormone release in castrated adult human males.
    Barbarino A; De Marinis L
    J Clin Endocrinol Metab; 1980 Aug; 51(2):280-6. PubMed ID: 6772661
    [No Abstract]   [Full Text] [Related]  

  • 32. [Medical therapy of cryptorchism: long-term results].
    Agostino A; Altomonte G; Vecci E; Poti C; Jacobelli A
    Clin Ter; 1983 Mar; 104(6):457-62. PubMed ID: 6133666
    [No Abstract]   [Full Text] [Related]  

  • 33. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
    Kobayashi T; Nishizawa K; Mitsumori K
    Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pituitary hormones in prostatic adenoma].
    Gerasimova TsI; Men'shikov VV; Buniatin AF; Smirnov AN; Bol'shakova TD
    Sov Med; 1985; (2):80-3. PubMed ID: 2581323
    [No Abstract]   [Full Text] [Related]  

  • 35. Getting over testosterone: postulating a fresh start for etiologic studies of prostate cancer.
    Carpenter WR; Robinson WR; Godley PA
    J Natl Cancer Inst; 2008 Feb; 100(3):158-9. PubMed ID: 18230791
    [No Abstract]   [Full Text] [Related]  

  • 36. The control of gonadotropin secretion in complete testicular feminization.
    Faiman C; Winter JS
    J Clin Endocrinol Metab; 1974 Oct; 39(4):631-8. PubMed ID: 4416135
    [No Abstract]   [Full Text] [Related]  

  • 37. Responses of serum levels of testicular steroid hormones to hCG stimulation in patients with prostatic cancer and benign prostatic hypertrophy.
    Isurugi K; Kanazawa M; Yanaihara T; Kambegawa A
    Prostate Suppl; 1981; 1():19-26. PubMed ID: 6176980
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A gonadotropin-responsive adrenocortical adenoma.
    Givens JR; Andersen RN; Wiser WL; Coleman SA; Fish SA
    J Clin Endocrinol Metab; 1974 Jan; 38(1):126-33. PubMed ID: 4358642
    [No Abstract]   [Full Text] [Related]  

  • 39. Kinetics of 3H-testosterone and 3H-dihydrotestosterone metabolism in patients with benign prostatic hypertrophy. Effect of cyproterone acetate.
    Hutschenreiter G; Sinterhauf K; Altwein JE
    Eur Urol; 1977; 3(2):100-4. PubMed ID: 67948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Percutaneous 17 beta-estradiol in treatment of cancer of prostate.
    Steg A; Benoit G
    Urology; 1979 Oct; 14(4):373-5. PubMed ID: 227153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.